Seeking Alpha

Halozyme Therapeutics (HALO +3.7%) moves higher after Barclays initiates coverage with a Buy...

Halozyme Therapeutics (HALO +3.7%) moves higher after Barclays initiates coverage with a Buy rating and $15 price target. Analyst Ying Huang highlights the firm's proven "proof-of-concept" for multiple molecules and promising pipeline. Shares are up 22% YTD and trade just below 52-week highs.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector